Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Madrigal Cements Case For Hepatic Fat Reduction, Other NASH Benefits With MGL-3196

Nov 13 2018

• By Joseph Haas

MedicineUnderAMicroscope_1200x675

Related Content

Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction

Dec 06 2017

Madrigal Believes It Holds The Key To NASH: Clearing The Fat

Mar 01 2017

Madrigal May Shake Up NASH Race With Phase II Resolution Data

May 31 2018

Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH

Sep 18 2018

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Jun 15 2018

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

Genfit May Be Gaining An Edge In NASH Race

Oct 26 2017

Related Companies

Madrigal Pharmaceuticals, Inc.

Viking Therapeutics, Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Allergan plc

Additional Topics

Clinical Trials Research & Development Business Strategies Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window